Drug intelligence / Profile preview

berberine + alpha lipoic acid + picrorhiza

Development stage
Unknown
Lead developer
Carmel Biosciences
Modality
Small Molecules
Administration
Oral
01

Overview

This is a combination dietary supplement containing **berberine**, **alpha-lipoic acid**, and **picrorhiza**. It is being studied under the name CAR-191 for its effects on appetite suppression, body composition, and weight control, as well as on the mechanistic effects of oxidation, inflammation, and vascular function, particularly in high-risk populations with metabolic syndrome[1][4]. Each active ingredient is administered in separate capsules (berberine 200 mg, alpha-lipoic acid 150 mg, picrorhiza 100 mg) taken three times daily before meals[1][4]. - **Berberine** acts via modulation of hepatic low-density lipoprotein receptor expression, improvement of endothelial function, and reduction in LDL cholesterol and glucose[5][7][9]. - **Alpha-lipoic acid** functions as an antioxidant and has demonstrated efficacy in improving diabetic neuropathy and reducing blood lipids[2][8]. - **Picrorhiza** is used in traditional medicine, primarily for liver-related disorders, and may have immunomodulatory and glucose-lowering properties[3][6]. The supplement is currently at the clinical investigation stage and is not an approved pharmaceutical[1][4].

Brand names
CAR-191CAR191CAR 191
Other names
berberine + alpha-lipoic acid + picrorhiza
02

Targets

AMPK (Adenosine monophosphate–activated protein kinase)NFE2L2 (Nuclear factor (erythroid-derived 2)-like 2)PDH (Pyruvate dehydrogenase complex)SLC2A4 (Solute carrier family 2 facilitated glucose transporter member 4)LDLR (Low-density lipoprotein receptor)PPARG (Peroxisome proliferator-activated receptor gamma)Misfolded SOD1

Beyond the preview

Go deeper on berberine + alpha lipoic acid + picrorhiza.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on berberine + alpha lipoic acid + picrorhiza.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call